BMP-5 Inhibitors
The chemical class of BMP-5 Inhibitors, while not directly targeting BMP-5, focuses on modulating the BMP/TGF-β signaling pathway, with which BMP-5 interacts. BMP-5 is involved in essential developmental processes, and its signaling is mediated through specific type I and type II serine/threonine kinase receptors. The inhibitors listed predominantly target BMP type I receptors such as ALK2, ALK3, and ALK6. Compounds like Dorsomorphin, LDN-193189, DMH1, and LDN-214117 inhibit these receptors, thereby indirectly affecting BMP-5 signaling. By blocking the receptor-mediated activation, these inhibitors can alter the downstream effects of BMP-5.
In addition to direct receptor inhibitors, some compounds modulate the broader BMP/TGF-β signaling pathways. For example, SB-431542, A-83-01, and Galunisertib inhibit TGF-β receptors, which can indirectly impact BMP-5 due to the crosstalk between TGF-β and BMP signaling. RepSox and SIS3 also function in this manner, targeting ALK5 and Smad3, respectively. Furthermore, proteins like Noggin, which naturally bind and inhibit BMPs, can indirectly modulate BMP-5 activity, although Noggin is not a chemical compound. FK506 (Tacrolimus), known as an immunosuppressant, has been observed to influence BMP signaling under certain conditions, potentially affecting BMP-5 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. This action can indirectly affect BMP-5 function by altering its signaling pathway. | ||||||
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 1432597-26-6 | sc-476318 | 5 mg | $380.00 | ||
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline is a more potent derivative of LDN-193189, selectively inhibiting BMP receptor ALK2, and to a lesser extent ALK3. It indirectly affects BMP-5 signaling by inhibiting these receptors. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 is a selective ALK2 inhibitor, designed to inhibit BMP signaling. This can have an indirect effect on BMP-5 activity by modulating its receptor-mediated signaling. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK506 (Tacrolimus) is primarily an immunosuppressant but has been shown to enhance BMP signaling in certain contexts. While it does not directly inhibit BMP-5, it can influence BMP-5 activity indirectly through its effects on the broader BMP signaling pathway. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299 inhibits TGF-β receptor ALK5. This can indirectly affect BMP-5 activity, as TGF-β and BMP pathways often have overlapping and interconnected roles. | ||||||
Smad3 Inhibitor, SIS3 | 1009104-85-1 | sc-222318 | 1 mg | $257.00 | 36 | |
SIS3 is a specific inhibitor of Smad3, which is a downstream effector in TGF-β signaling. Its inhibition can indirectly influence BMP-5 activity due to the crosstalk between TGF-β and BMP signaling pathways. | ||||||